Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion

British Journal of Ophthalmology

Volumn 95, Issue 6, 2011, Pages 788-792

  Noma, Hidetaka ^a   Funatsu, Hideharu ^a   Mimura, Tatsuya ^b   Eguchi, Shuichiro ^c   Shimada, Katsunori ^d  

^a Tokyo Women s Medical University   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Eguchi Eye Hospital   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

AGED; ARTICLE; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; MALE; MEMBRANE PERMEABILITY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA ISCHEMIA; RETINA MACULA EDEMA; RETINA MACULA HOLE; TISSUE LEVEL; VITREORETINAL SURGERY; VITREOUS BODY;

AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; MACULAR EDEMA; MALE; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VITREOUS BODY;

EID: 79956364212     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.192468     Document Type: Article

References (27)

1. Hayreh SS. Classification of central retinal vein occlusion. Ophthalmology 1983;90:458-74. (Pubitemid 13059774)
2. Gutman FA, Zegarra H. Macular edema secondary to occlusion of the retinal veins. Surv Ophthalmol 1984;28(Suppl):462-70. (Pubitemid 14076505)
3. Zegarra H, Gutman FA, Conforto J. The natural course of central retinal vein occlusion. Ophthalmology 1979;86:1931-42.
4. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology 2009;116:87-93.
5. Noma H, Funatsu H, Mimura T, et al. Aqueous humor levels of vasoactive molecules correlate with vitreous levels and macular edema in central retinal vein occlusion. Eur J Ophthalmol 2010;20:402-9.
6. Noma H, Funatsu H, Mimura T, et al. Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion. Acta Ophthalmol 2010;88:646-51.
7. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 2006;26:279-84. (Pubitemid 44318180)
8. Pai SA, Shetty R, Vijayan PB, et al. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 2007;143:601-6.
9. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-9. (Pubitemid 351426182)
10. Ach T, Hoeh AE, Schaal KB, et al. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010;248:155-9.
11. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-33 e1.
12. Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276:3222-30.
13. Leizaola-Fernandez C, Suarez-Tata L, Quiroz-Mercado H, et al. Vitrectomy with complete posterior hyaloid removal for ischemic central retinal vein occlusion: series of cases. BMC Ophthalmol 2005;5:10.
14. Tachi N, Hashimoto Y, Ogino N. Vitrectomy for macular edema combined with retinal vein occlusion. Doc Ophthalmol 1999;97:465-9.
15. The Central Vein Occlusion Study. Baseline and early natural history report. Arch Ophthalmol 1993;111:1087-95.
16. The Central Vein Occlusion Study Group M report. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology 1995;102:1425-33.
17. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997;115:486-91.
18. Otani T, Kishi S. Tomographic assessment of vitreous surgery for diabetic macular edema. Am J Ophthalmol 2000;129:487-94. (Pubitemid 30184920)
19. Spoerri PE, Afzal A, Li Calzi S, et al. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells. Mol Vis 2006;12:32-42.
20. Ojima T, Takagi H, Suzuma K, et al. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am J Pathol 2006;168:331-9. (Pubitemid 43062584)
21. Kim JH, Lee YM, Ahn EM, et al. Decursin inhibits VEGF-mediated inner blood-retinal barrier breakdown by suppression of VEGFR-2 activation. J Cereb Blood Flow Metab 2009;29:1559-67.
22. Scheppke L, Aguilar E, Gariano RF, et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J Clin Invest 2008;118:2337-46. (Pubitemid 351872350)
23. White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens 1999;12:50S-5S.
24. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-32.
25. Yoshimura T, Sonoda KH, Sugahara M, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158.
26. Belgore FM, Blann AD, Li-Saw-Hee FL, et al. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential hypertension. Am J Cardiol 2001;87:805-7. (Pubitemid 32209107)
27. Li B, Ogasawara AK, Yang R, et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002;39:1095-100. (Pubitemid 34620130)